Please assess the completion status of the following clinical trial:

Trial Title: CARAT: Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Post Roux-n-Y gastric bypass (RYGB) surgery and sleeve gastrectomy (SG) patients who underwent surgery \>1 and \<15 years ago in the Cleveland surrounding area~* Age 20-75 years of age~* Type II Diabetes Mellitus (D2M) diagnosis (history, medication usage, biochemical criteria) prior to and after surgery; after surgery, defined by a single HbA1c of greater or equal to 6.5% at consent and screening.~* Metformin patients must have an HbA1c greater than or equal to 6.5% but less than or equal to 10% at randomization; for diet controlled patients (i.e. not on any T2D medication), HbA1c must be greater than or equal to 6.5% at randomization.~* Patient reporting of improvement in T2D status or objective improvements in T2D status at any time post-surgery.~* estimated glomerular filtration rate (eGFR) ≥ 60mL/min prior to randomization~* Has the ability and willingness to provide informed consent.~* Is able to understand the options and to comply with the requirements of each program~* Female subject agrees to have a serum pregnancy test at screening. A negative serum pregnancy test result is required prior to randomization.~* Female patients must agree to use a reliable method of contraception for 6 months or duration of intervention~* Patients taking an anti-diabetic medication, except insulin, are eligible and must agree to washout for 8 weeks prior to the randomization visit.~Exclusion Criteria:~* Type 1 diabetes indicated by history of diabetic ketoacidosis and lack of remission in response to bariatric surgery~* Other post bariatric procedures (banding, duodenal switch, biliopancreatic diversion)~* Current use of insulin.~* End organ diabetic complications (renal failure, cardiomyopathy, severe neuropathy/foot ulcers)~* Documented severe or unstable depression/anxiety or eating disorder that would not enable patient to adhere to anti-diabetic treatment~* Clinical contraindications to use canagliflozin, i.e., history of bladder cancer, Child-Pugh class C

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Study Drug (canagliflozin) (Type: ACTIVE_COMPARATOR): Subjects randomized to study drug will be assigned a six month course starting on canagliflozin 100 mg for two weeks titrated up to 300 mg daily (n= 24).
- Placebo (Type: PLACEBO_COMPARATOR): Subjects randomized to placebo will be assigned a six month course of one placebo pill daily (n =12).

Based on this trial design, predict the completion outcome and termination type (if applicable).